[1]
Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet 2016; 387(10013): 70-82.
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5-29.
[3]
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65(1): 124-37.
[4]
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71(4): 618-29.
[5]
KandaSwamy GV, Bennett A, Narahari K, Hughes O, Rees J, Kynaston H. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort. BJU Int 2017; 120(5B): E59-63.
[6]
Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent Prostate Cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol 2012; 2012921674
[7]
Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized Prostate-Cancer screening trial. N Engl J Med 2009; 360(13): 1310-9.
[8]
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3(1): 81-5.
[9]
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995; 1(1): 18-28.
[10]
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52(4): 637-40.
[11]
Kularatne SA, Zhou Z, Yang J, Post CB, Low PS. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm 2009; 6(3): 790-800.
[12]
Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 2011; 17(24): 7645-53.
[13]
Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69(17): 6932-40.
[14]
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91(3): 528-39.
[15]
Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3(4): 216-25.
[16]
Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51(15): 4504-17.
[17]
Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a Urea-Based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23(4): 688-97.
[18]
Schreiter V, Gericke M, Heimann U, et al. Comparison of [68Ga]Ga-PSMA-HBED-CC PET versus whole-body bone scintigraphy for the detection of bone metastases in patients with prostate cancer. J Nucl Med Radiat Ther 2016; 7(5): 1-6.
[19]
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47(2): 287-97.
[20]
Rowe SP, Mana-Ay M, Javadi MS, et al. PSMA-based detection of prostate cancer bone lesions with 18F-DCFPyL PET/CT: A sensitive alternative to (99m)Tc-MDP bone scan and Na18F PET/CT? Clin Genitourin Cancer 2016; 14(1): e115-8.
[21]
Lavalaye J, Kaldeway P, van Melick HH. Diffuse bone metastases on (68)Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan. Eur J Nucl Med Mol Imaging 2016; 43(8): 1563-4.
[22]
Freitag MT, Radtke JP, Hadaschik BA, et al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43(1): 70-83.
[23]
Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43(12): 2114-21.
41
2